STOCK TITAN

BBIO (NASDAQ: BBIO) — Trustee and Insider 10b5-1 Sales Listed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BBIO proposes the sale of 140,000 shares of Common stock as indicated on the notice.

The filing lists multiple prior 10b5-1 sales by related parties, including recent transactions by Kumar Haldea Revocable Trust and Neil Kumar on 03/12/2026 and 02/19/2026. Examples shown include 20,000 shares sold on 03/12/2026 and 28,053 shares sold on 02/19/2026.

Positive

  • None.

Negative

  • None.

Insights

Notice documents proposed resale of 140,000 shares and lists prior 10b5-1 sales.

The notice identifies a 140,000 share amount of Common stock associated with the filing and documents prior executed 10b5-1 sales by related trusts and an individual on explicit dates. The filing text ties specific sale dates and share counts to named trust and individual sellers.

Legal implications primarily concern compliance with Rule 144 transfer restrictions and the documented automatic-plan sales; timing and proceeds treatment are as stated in the form. Subsequent filings would show settlement details if and when sales occur.

Routine resale notification with documented rule‑based sales; transaction scale is modest relative to typical floats.

The filing lists multiple prior sales executed under 10b5-1 plans with per-trade proceeds shown (for example 1,374,660.00 on 03/12/2026). The primary action is a registration/notice of up to 140,000 shares.

Cash-flow treatment and any issuer proceeds are not itemized here; market impact depends on actual execution and remaining holdings disclosed in other filings. Further position detail would appear in Form 4/5 or later disclosures.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the BBIO Form 144 disclose?

The Form 144 discloses a proposed sale of 140,000 shares of Common stock and lists prior 10b5-1 sales by related parties on specific dates, including transactions on 03/12/2026 and 02/19/2026.

Who executed recent 10b5-1 sales listed in the filing for BBIO?

Recent listed sales were executed by entities including Kumar Haldea Revocable Trust, Kumar Haldea Family Irrevocable Trust, and Neil Kumar, with trade dates such as 03/12/2026 and 02/19/2026.

How large were example trades shown in the BBIO filing?

Example trades include sales of 20,000 shares on 03/12/2026 with proceeds around 1,374,660.00 and 28,053 shares on 02/19/2026 with proceeds around 2,002,717.70, as listed in the form.

Does the Form 144 state who receives proceeds for these BBIO sales?

The filing lists the selling parties by name (trusts and an individual) and per-trade proceeds; it does not state issuer receipt of proceeds or use of proceeds in this excerpt.
Bridgebio Pharma

NASDAQ:BBIO

View BBIO Stock Overview

BBIO Rankings

BBIO Latest News

BBIO Latest SEC Filings

BBIO Stock Data

13.18B
167.90M
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO